- Home
- OFLX vs DSGN Comparison
OFLX vs DSGN Comparison
Compare OFLX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- DSGN
- Stock Information
- Founded
- OFLX 1975
- DSGN 2017
- Country
- OFLX United States
- DSGN United States
- Employees
- OFLX N/A
- DSGN N/A
- Industry
- OFLX Industrial Specialties
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- DSGN Health Care
- Exchange
- OFLX Nasdaq
- DSGN Nasdaq
- Market Cap
- OFLX 374.3M
- DSGN 348.2M
- IPO Year
- OFLX 2005
- DSGN 2021
- Fundamental
- Price
- OFLX $34.78
- DSGN $3.86
- Analyst Decision
- OFLX
- DSGN Buy
- Analyst Count
- OFLX 0
- DSGN 2
- Target Price
- OFLX N/A
- DSGN $8.00
- AVG Volume (30 Days)
- OFLX 27.1K
- DSGN 139.5K
- Earning Date
- OFLX 03-05-2025
- DSGN 03-10-2025
- Dividend Yield
- OFLX 3.80%
- DSGN N/A
- EPS Growth
- OFLX N/A
- DSGN N/A
- EPS
- OFLX 1.78
- DSGN N/A
- Revenue
- OFLX $101,681,000.00
- DSGN N/A
- Revenue This Year
- OFLX N/A
- DSGN N/A
- Revenue Next Year
- OFLX N/A
- DSGN N/A
- P/E Ratio
- OFLX $19.81
- DSGN N/A
- Revenue Growth
- OFLX N/A
- DSGN N/A
- 52 Week Low
- OFLX $34.39
- DSGN $3.15
- 52 Week High
- OFLX $75.15
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- OFLX 32.75
- DSGN 35.64
- Support Level
- OFLX $37.36
- DSGN $4.06
- Resistance Level
- OFLX $39.64
- DSGN $5.09
- Average True Range (ATR)
- OFLX 1.40
- DSGN 0.36
- MACD
- OFLX -0.47
- DSGN -0.10
- Stochastic Oscillator
- OFLX 2.60
- DSGN 0.58
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.